Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ

Open source

DOI: 10.3324/haematol.2018.194282
Published: 2018 Dec
Container: Haematologica
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2018.194282,
  title = {Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.},
  author = {Dimopoulos MA and San-Miguel J and Belch A and White D and Benboubker L and Cook G and Leiba M and Morton J and Ho PJ and Kim K and Takezako N and Moreau P and Kaufman JL and Sutherland HJ and Lalancette M and Magen H and Iida S and Kim JS and Prince HM and Cochrane T and Oriol A and Bahlis NJ and Chari A and O'Rourke L and Wu K and Schecter JM and Casneuf T and Chiu C and Soong D and Sasser AK and Khokhar NZ and Avet-Loiseau H and Usmani SZ},
  year = {2018},
  journal = {Haematologica},
  doi = {10.3324/haematol.2018.194282},
  url = {https://doi.org/10.3324/haematol.2018.194282}
}

RIS

TY  - JOUR
TI  - Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
AU  - Dimopoulos MA
AU  - San-Miguel J
AU  - Belch A
AU  - White D
AU  - Benboubker L
AU  - Cook G
AU  - Leiba M
AU  - Morton J
AU  - Ho PJ
AU  - Kim K
AU  - Takezako N
AU  - Moreau P
AU  - Kaufman JL
AU  - Sutherland HJ
AU  - Lalancette M
AU  - Magen H
AU  - Iida S
AU  - Kim JS
AU  - Prince HM
AU  - Cochrane T
AU  - Oriol A
AU  - Bahlis NJ
AU  - Chari A
AU  - O'Rourke L
AU  - Wu K
AU  - Schecter JM
AU  - Casneuf T
AU  - Chiu C
AU  - Soong D
AU  - Sasser AK
AU  - Khokhar NZ
AU  - Avet-Loiseau H
AU  - Usmani SZ
PY  - 2018
JO  - Haematologica
DO  - 10.3324/haematol.2018.194282
UR  - https://doi.org/10.3324/haematol.2018.194282
ER  -

APA

MA, D., J, S., A, B., D, W., L, B., G, C., M, L., J, M., PJ, H., K, K., N, T., P, M., JL, K., HJ, S., M, L., H, M., S, I., JS, K., HM, P., T, C., A, O., NJ, B., A, C., L, O., K, W., JM, S., T, C., C, C., D, S., AK, S., NZ, K., H, A., & SZ, U. (2018). Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.. Haematologica. https://doi.org/10.3324/haematol.2018.194282

Source records

pubmed · retrieved 2026-09-25T22:47:31.025Z